ADORA2A and Alzheimer disease: Moreover, our group demonstrated that in rodent AD models, consisting in the intracerebroventricular Aβ injection, both caffeine and the selective A2AR antagonist SCH58261 prevent Aβ-induced cognitive impairments and synaptotoxicity (Dall’lgna et al., 2007; Cunha et al., 2008; Canas et al., 2009).